Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Radium-223, Abiraterone to be Studied in Combination

July 9th 2014

Two recently approved drugs for the treatment of advanced prostate cancer-radium-223 (Xofigo) and abiraterone acetate (Zytiga)-will be studied in combination in a phase III clinical trial.

Thomas A. Neville, PhD, Discusses PSA Growth Rate

July 8th 2014

Thomas A. Neville, PhD, CEO of Soar Biodynamics in Incline Village, Nevada, discusses PSA growth rate.

Dr. Moul Discusses the Long-Term Tolerability and Efficacy of Degarelix

July 3rd 2014

Judd W. Moul, MD, director, Duke Prostate Center, James H. Semans, MD, Professor of Surgery, Duke University Medical Center, discusses the 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix

Is Death From Prostate Cancer the Right Clinical Endpoint to Guide Screening and Treatment Choices?

July 3rd 2014

There are few controversies in oncology as divisive as the value of prostate-specific antigen (PSA) screening and subsequent treatment for prostate cancer.

Dr. Einhorn on Improving the Cure Rate and the Burden of Cure in Prostate Cancer

July 1st 2014

Lawrence H. Einhorn, MD, distinguished professor of medicine, division of hematology/oncology, Indiana University School of Medicine, Giant of Cancer Care: Genitourinary Cancer, discusses new methods being explored to help improve the cure rate in prostate cancer.

With ADT in PC, Managing Side Effects Increasingly Important

July 1st 2014

Androgen-deprivation therapy (ADT) is a mainstay of treatment for prostate cancer in a number of settings, so managing its side effects is becoming increasingly important for urologists in collaboration with oncologists and primary-care physicians.

Blood Test Predicts Resistance to Enzalutamide in mCRPC

June 23rd 2014

It may be possible to predict which men with metastatic castration-resistant prostate cancer will not respond to enzalutamide by using a simple blood test to detect the presence of AR-V7 in circulating tumor cells.

Docetaxel May Cause Intoxication, FDA Warns

June 20th 2014

The FDA has issued a drug safety communication regarding the risk of intoxication with the intravenous ethanol-containing chemotherapy docetaxel.

Dr. Yu Discusses Observation Versus Treatment in Men with Prostate Cancer

June 13th 2014

Peter Yu, MD, director, Palo Alto Medical Foundation, president-elect, ASCO, discusses results of a review that examined men's treatment decisions after seeing a raise in their PSA levels.

Promising Biomarkers Emerging Across the Spectrum of Prostate Cancer Care

June 12th 2014

Researchers are making progress in identifying biomarkers and developing assays that will help clinicians improve the management of patients with prostate cancer from screening strategies to making therapy choices

Dr. Posadas Discusses Cabozantinib in Prostate Cancer

June 11th 2014

Edwin M. Posadas, MD, FACP, medical director, Urologic Oncology Program, Cedars-Sinai's Samuel Oschin Comprehensive Cancer Institute, discusses a translational phase II study of cabozantinib in men with metastatic castration-resistant prostate cancer(mCRPC) with visceral metastases with characterization of circulating tumor cells and large oncosomes.

Androgen Deprivation Therapy and Cardiovascular Risk in Prostate Cancer

June 11th 2014

Accumulating evidence suggests that androgen deprivation therapy for prostate cancer increases the risk of cardiovascular morbidity and mortality, though not all studies demonstrate an association

Vogelzang Sees Early Chemo Strategy as Landmark Change in Prostate Cancer Therapy

June 10th 2014

Ten years ago, Nicholas J. Vogelzang, MD, helped design a study of docetaxel added to first-line androgen deprivation therapy (ADT) in men with newly diagnosed metastatic, hormone-sensitive prostate cancer.

A Sizable Success: UroPartners Balances Operation of Large Practice with Provision of Singular Care

June 9th 2014

One of the ongoing debates in US politics involves the pros and cons of big government versus small government: Does big automatically equal bureaucracy and groupthink while small inherently fosters individual creativity and enterprise?

Dr. Vogelzang Discusses the Addition of Chemotherapy to ADT in Men With Prostate Cancer

June 9th 2014

Nicholas J. Vogelzang, MD,discusses results from the phase III CHAARTED (E3805) study that examined the addition of chemotherapy to androgen deprivation therapy (ADT) for the treatment of men with newly diagnosed metastatic, hormone-sensitive prostate cancer.

Novel Imaging Techniques for Metastatic Prostate Cancer Advance

June 9th 2014

Improved imaging modalities are needed to help advance treatment of men diagnosed with metastatic prostate cancer, and several novel techniques are under study

2014 NCCN Guideline Updates: Experts Highlight New Recommendations for Clinical Practice

June 6th 2014

At the recent National Comprehensive Cancer Network (NCCN) 19th Annual Conference, experts discussed this year's updates to the NCCN Clinical Practice Guidelines in Oncology. The meeting also included reviews of NCCN Task Force reports on issues in supportive care. We asked eleven NCCN panel members to select the most significant updates and insights presented at the conference.

Radium 223 Option Hinges on Bony Disease Burden in mCRPC

June 5th 2014

As with other new therapies that have been approved in recent years for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), researchers are not entirely certain about how best to fit radium Ra 223 dichloride (Xofigo) into the emerging paradigm

Adding Chemo to ADT Confers Dramatic Survival Gains in Prostate Cancer

June 1st 2014

In what was described as "an almost unprecedented improvement in median survival," the addition of the chemotherapy drug docetaxel to standard hormone therapy prolonged life for men with newly diagnosed metastatic, hormone-sensitive prostate cancer by nearly 14 months.

Dr. Hussain on ETS Gene Fusions as a Predictive Biomarker in Prostate Cancer

May 31st 2014

Maha Hussain, MD, from the University of Michigan Comprehensive Cancer Center, discusses the possibility of ETS gene fusions acting as a predictive biomarker for prostate cancer.